In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 36 days of free consultation

 

Non-valvular atrial fibrillation (AF) and coronary artery disease with percutaneous revascularisation: safety of triple therapy with dabigatran

Session Poster Session 2

Speaker Macarena Cano-Garcia

Congress : Acute Cardiovascular Care 2019

  • Topic : cardiovascular pharmacology
  • Sub-topic : Anticoagulants
  • Session type : Poster Session
  • FP Number : P641

Authors : M Cano-Garcia (Malaga,ES), JA Cano Nieto (Malaga,ES), JL Delgado Prieto (Malaga,ES), JM Perez Ruiz (Malaga,ES), M De Mora Martin (Malaga,ES), CA Urbano Carrillo (Malaga,ES)

15 views

Authors:
M Cano-Garcia1 , JA Cano Nieto1 , JL Delgado Prieto1 , JM Perez Ruiz1 , M De Mora Martin1 , CA Urbano Carrillo1 , 1Regional University Hospital Carlos Haya, Cardiology - Malaga - Spain ,

Citation:

Background: Patients who require oral anticoagulation and who also need a percutaneous coronary intervention present a challenge for the cardiologist at present. Despite the fact that NACOs began to be used several years ago, data on triple therapy safety are scarce.

Purpose: The aim of our study was to analyze the safety and efficacy of triple therapy combined with ASA, clopidogrel and dabigatran, analyzing the percentage of bleeding during follow-up.

Methods: Prospective and monocentric study. We included patients with indication for anticoagulation for non-valvular AF, in whom at least one coronary stent was implanted. At discharge they were prescribed treatment with acetylsalicylic acid 100mg / 24h + clopidogrel 75mg / 24h + dabigatran 110mg / 12h. The duration of the triple therapy was carried out according to the ESC clinical practice guidelines for atrial fibrillation (2016). The incidence of bleeding, stent thrombosis, need for revascularization and cardiovascular death was analyzed.

Methods: Forty-three patients were included between February 2017 and January 2018, age 71.7 ± 8.9 years and high prevalence of risk factors (hypertension 81.4%, dyslipidemia 74.4%, diabetes mellitus 58.1%). 46.5% with paroxysmal AF, 18.6% persistent AF and 34.9% with permanent AF (with a median CHA2DS2VASC 4 and HASBLEED 3). The indication for PCI was elective in 11 patients (25.6%) and acute coronary syndrome in 32 patients (74.4%). The type of stent used was: bare metal stent in 15 patients (34.8%) and drug-eluting stent in 28 patients (65.1%). An average of 1.3 ± 0.6 lesions/ atient was treated with an average of 1.5 ± 0.9 stents  esion. The mean diameter of the implanted stents was 2.7 ± 0.  and the average length of the stented segment was 30.8 ± 17.3 mm. After a follow-up of 6.2 ± 2.9 months, 5 bleedings (11.6%) were observed: 2 digestive bleeds with a need for transfusion (4.6%) and 3 epistaxis (6.9%). The observed events were: non-fatal AMI in a different coronary artery 1 patient (2.3%), need for revascularization of target lesion in 2 patients (4.6%). There was not stent thrombosis or deaths. The only variable associated with the incidence of bleeding was the previous hematocrit (OR 0.58, 95% CI, 0.187-0.982, p = 0.04).

Conclusions: In this study, the use of triple therapy with dabigatran has been shown to be safe and effective, with a low percentage of bleeding requiring transfusion compared to previous studies.

This content is currently on FREE ACCESS, enjoy another 36 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are